Lexicon Pharmaceuticals Inc

NASDAQ:LXRX  
8.50
+0.02 (+0.24%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.21B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.08 Million
Adjusted EPS-$0.29
See more estimates
10-Day MA$7.05
50-Day MA$3.38
200-Day MA$2.17
See more pivots

LEXICON PHARMACEUTICALS, INC. Stock, NASDAQ:LXRX

8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS, TX 77381
United States of America
Phone: 2818633000
Number of Employees: 202

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.